SIA
ARQT icon

Sit Investment Associates’s Arcutis Biotherapeutics ARQT Stock Holding History

Sit Investment Associates’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$758K Hold
28,900
– – 0.01% 384
2026
Q1 		$681K Buy
28,900
+15,950
+123% +$407K 0.01% 394
2025
Q4 		$376K Buy
+12,950
New +$332K 0.01% 425

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Sit Investment Associates's ARQT Position: Q2 2026 in Review

Sit Investment Associates held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 28,900 shares worth $758K. The position accounts for 0.01% of the portfolio, ranked #384.

Sit Investment Associates first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Sit Investment Associates held 28,900 shares of Arcutis Biotherapeutics worth $758K as of Q2 2026.
  • Sit Investment Associates left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up 0.01% of Sit Investment Associates's portfolio in Q2 2026, its #384 holding.
  • Sit Investment Associates first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Sit Investment Associates's 13F filing for Q2 2026, filed 12 Aug 2026.